



**OFFICIAL**

**RECEIVED  
CENTRAL FAX CENTER**

Legal Division  
Pfizer Inc.  
235 East 42nd Street  
New York, NY 10017

APR 19 2004

**Facsimile Transmission**

**NOTICE OF CONFIDENTIALITY**

This transmission is intended only for the use of the Addressee and may contain information that is: 1. Subject to attorney/client privilege; 2. Attorney work product; or 3. Confidential. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of the information contained in this facsimile is strictly unauthorized and prohibited. If you have received this facsimile in error, please notify us immediately by collect telephone call to the sender named below. Thank you.

**To: EXAMINER JIANG**

**Location: USPTO**

**Facsimile Telephone: 1-703-872-9306**

**No. of Pages: (including this page): 6**

**From: Andrea E. Dorigo, Esq. - REG. NO. 47,532**

**Department Name: Legal Division**

**Charge No.: 88424**

**Facsimile Telephone: (212) 573-1939**

**Date: April 19, 2004**

**Time (New York) 10:34 AM**

**TO CONFIRM RECEIPT OF TRANSMISSION, CALL 212 733-1898 or 212-733-1898**

**Re: PC10244A - DECLARATION**

FAX COVER SHEET (LEGAL DIVISION), 3/99

Attorney Docket No. PC10244A USA

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

IN RE APPLICATION OF:	Obach, R. S.	:	
APPLICATION NO.:	09/528,978	:	Examiner: Jiang
FILING DATE:	3/21/2000	:	Group Art Unit: 1617
TITLE:	USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES	:	

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUBMISSION OF DECLARATION UNDER 37 CFR 1.132**

Sir:

Applicants submit herewith a Declaration under 37 CFR 1.132 following a telephone communication by Examiner Jiang to the undersigned attorney for Applicants.

A Declaration under 37 CFR 1.132 was originally filed on December 18 2003 together with a Response to the Final Official Action. According to the telephone communication by Examiner Jiang to the undersigned attorney for Applicants referred to above, the Declaration filed was not persuasive. Accordingly, Applicants submit a new Declaration under 37 CFR 1.132, which is enclosed herewith.


In view of the foregoing, allowance of Claim 1, pending in the application, is respectfully requested.

Attorney Docket No. PC10244A USA

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R.  
§§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445.

Respectfully submitted,

Date: April 9 2004

  
\_\_\_\_\_  
Andrea Dorigo  
Attorney for Applicant(s)  
Reg. No. 47,532

Pfizer Inc  
Patent Department  
150 East 42nd Street – 5<sup>th</sup> Floor  
New York, NY 10017-5755  
(212) 733-1898